Sign Out
Use of this drug may be associated with electrolyte disturbances including hypokalemia, hypercalcemia, and/or hypomagnesemia. Closely monitor electrolytes during therapy and discontinue if potassium ≤5 mmol/L (5 mEq/L).
Sudden increases in calcium may be observed with use in renal impairment and/or dialysis patients.
Monitor calcium weekly or more frequently if clinically indicated.
Discontinue use of clinically significant constipation.
Avoid magnesium containing laxatives.
Use of similar agent (e.g. sodium polystyrene sulfonate) with sorbital enema may cause colon necrosis or intestinal obstruction. Therefore, avoid concomitant use of rectal sorbital.
